Aurélien Rizk ^UDM

Aurélien Rizk is the CSO and co-founder of InterAx Biotech, contributing to the company's focus on drug discovery. As a scientist and entrepreneur, he has a background in developing mathematical modeling, numerical simulations, and AI methods for drug discovery. InterAx Biotech, a spin-out of ETH Zurich and the Paul Scherrer Institute, specializes in high-throughput biochemical screening of compounds integrated into an artificial intelligence and cell pathways mathematical modeling process. The company's platform aims to unlock previously intractable targets, shorten timelines for drug discovery, and reduce risks. Specializing in GPCR drug discovery, InterAx AG has a highly experienced team of scientists with expertise in AI, mathematical models of signaling pathways, cellular pharmacology, and computational chemistry.